Cancer discovery
The most recent articles from:
Cancer Discov
-
England's Cancer Drugs Fund will reduce the number of indications it pays for by nearly 30%. Projections suggested that the cost of the fund would have more than doubled by the end of the year, and the cuts will save £80 million ($121 million) by eliminating drugs such as eribulin and ziv-aflibercept.
-
Randomized Controlled Trial
Pictilisib stalls advanced ER+/PR+ breast cancer.
-
The experimental drug AG-120, which inhibits mutant IDH1, showed promising results in a phase I trial in patients with relapsed or refractory acute myeloid leukemia.